Sunday, October 02, 2022 3:23:59 PM
“The Special 510(k) Program” guidance document, issued in September 2019, describes an optional pathway for manufacturers that make certain well-defined modifications to their own legally marketed device. The guidance was developed to clarify existing policy and the types of changes that are appropriate for the program in an effort to improve the efficiency of 510(k) review, consistent with the FDA’s least burdensome principles. The program allows FDA and industry to rely on previous agency review of detailed information and manufacturers to provide the minimum required information necessary to establish substantial equivalence (SE) for a modified device. As a result, special 510(k)s are processed within 30 days of receipt by the Document Control Center instead of 90 days as for Traditional or Abbreviated 510(k)s.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM